Clinical impact of vancomycin-resistant enterococci

Research output: Contribution to journalArticle

133 Citations (Scopus)

Abstract

In humans, vancomycin-resistant enterococci (VRE) most commonly result in intestinal colonization, which does not result in symptoms, may persist for a long time and serves as a reservoir for transmission of VRE to other patients. Certain VRE-colonized patients are at risk of infection, including haematology and oncology patients, patients in intensive care units and recipients of solid (especially abdominal) organ transplants. Controlling the spread of VRE colonization and preventing colonized patients from becoming infected are important aims. Ramoplanin is a member of a new class of antimicrobial agents; it may have a role in preventing infection in patients colonized with VRE.

Original languageEnglish (US)
JournalJournal of Antimicrobial Chemotherapy
Volume51
Issue numberSUPPL. 3
StatePublished - Jun 1 2003

Fingerprint

ramoplanin
Hematology
Anti-Infective Agents
Infection
Intensive Care Units
Vancomycin-Resistant Enterococci
Transplants

Keywords

  • Enterococci
  • Glycopeptide resistance
  • Vancomycin

ASJC Scopus subject areas

  • Pharmacology
  • Microbiology

Cite this

Clinical impact of vancomycin-resistant enterococci. / Patel, Robin.

In: Journal of Antimicrobial Chemotherapy, Vol. 51, No. SUPPL. 3, 01.06.2003.

Research output: Contribution to journalArticle

@article{fa310e2f3f27461290a4c4f5b68946f4,
title = "Clinical impact of vancomycin-resistant enterococci",
abstract = "In humans, vancomycin-resistant enterococci (VRE) most commonly result in intestinal colonization, which does not result in symptoms, may persist for a long time and serves as a reservoir for transmission of VRE to other patients. Certain VRE-colonized patients are at risk of infection, including haematology and oncology patients, patients in intensive care units and recipients of solid (especially abdominal) organ transplants. Controlling the spread of VRE colonization and preventing colonized patients from becoming infected are important aims. Ramoplanin is a member of a new class of antimicrobial agents; it may have a role in preventing infection in patients colonized with VRE.",
keywords = "Enterococci, Glycopeptide resistance, Vancomycin",
author = "Robin Patel",
year = "2003",
month = "6",
day = "1",
language = "English (US)",
volume = "51",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Clinical impact of vancomycin-resistant enterococci

AU - Patel, Robin

PY - 2003/6/1

Y1 - 2003/6/1

N2 - In humans, vancomycin-resistant enterococci (VRE) most commonly result in intestinal colonization, which does not result in symptoms, may persist for a long time and serves as a reservoir for transmission of VRE to other patients. Certain VRE-colonized patients are at risk of infection, including haematology and oncology patients, patients in intensive care units and recipients of solid (especially abdominal) organ transplants. Controlling the spread of VRE colonization and preventing colonized patients from becoming infected are important aims. Ramoplanin is a member of a new class of antimicrobial agents; it may have a role in preventing infection in patients colonized with VRE.

AB - In humans, vancomycin-resistant enterococci (VRE) most commonly result in intestinal colonization, which does not result in symptoms, may persist for a long time and serves as a reservoir for transmission of VRE to other patients. Certain VRE-colonized patients are at risk of infection, including haematology and oncology patients, patients in intensive care units and recipients of solid (especially abdominal) organ transplants. Controlling the spread of VRE colonization and preventing colonized patients from becoming infected are important aims. Ramoplanin is a member of a new class of antimicrobial agents; it may have a role in preventing infection in patients colonized with VRE.

KW - Enterococci

KW - Glycopeptide resistance

KW - Vancomycin

UR - http://www.scopus.com/inward/record.url?scp=0038601540&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038601540&partnerID=8YFLogxK

M3 - Article

C2 - 12801938

AN - SCOPUS:0038601540

VL - 51

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - SUPPL. 3

ER -